Contingency Management with pharmacologic treatment for Stimulant Use Disorders: A review

Tardelli, Vítor S.; Lago, Mariana Pimentel Pádua do; Mendez, Mariel; Bisaga, Adam; Fidalgo, Thiago M.

doi:10.1016/j.brat.2018.10.002

Cited by 19 publications

(17 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With these limitations, the psychosocial model of treatment has failed to increase patients' adherence and to address each patient needs, as the interventions tend to be highly standardized. 64,[68][69][70][71][72][73][74][75] Residential programs are another treatment model that also faces several obstacles. Usually, they are not associated with general health care facilities and often do not have adequate medical support, which may leave patients with severe health conditions caused by stimulants use and withdrawal untreated (75).…”

Section: Although Psychosocial Interventions Such As CM Remain the Mo...mentioning

confidence: 99%

“…Because lisdexamfetamine has not been extensively tested as a treatment for stimulant use disorder and considering its lesser abuse potential compared to other prescription amphetamines, 63 this can be a promising direction for future clinical studies. Moreover, the association of pharmacotherapy with PPs and evidence‐based psychosocial approaches should be explored in future trials 9,64 . Similar to many treatment trials in substance use disorders, most of the trials using PPs for cocaine use disorder excluded individuals with significant psychiatric comorbidities, which compromises the generalizability of those findings to community treatment settings.…”

Section: The Current State Of Evidence For Clinical Use Of Pps For Th...mentioning

confidence: 99%

“…Although psychosocial interventions such as CM remain the most effective interventions for CUD to date, these interventions usually do not reach patients in more vulnerable situations. With these limitations, the psychosocial model of treatment has failed to increase patients' adherence and to address each patient needs, as the interventions tend to be highly standardized 64,68–75 …”

Section: A (Not So) New Care‐model Proposalmentioning

confidence: 99%

See 2 more Smart Citations

Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach

et al. 2023

Self Cite

View full text Add to dashboard Cite

Cocaine use is a public health concern in many countries worldwide, particularly in the Americas and Oceania. Overdose deaths involving stimulants, such as cocaine, have been increasing markedly in North America, especially with concurrent opioid involvement. To date, no pharmacological treatment is available to treat stimulant (including cocaine) use disorders. Prescription psychostimulants (PPs) could be useful to treat cocaine use disorder (CUD) as they share the pharmacological effects with cocaine, as evidenced by a recent meta‐analysis that assessed 38 randomized clinical trials (RCTs). PPs were found to promote sustained abstinence and reduce drug use in patients with CUD. The aim of this paper is to provide a narrative review of the clinical pharmacology of PPs and comment on the current stage of evidence supporting PPs to treat CUD. We also propose a model of care that integrates PPs with evidence‐based psychosocial interventions (such as cognitive‐behavioural therapy [CBT] and contingency management [CM]), a harm reduction approach and case management with social support.

show abstract

Section: Although Psychosocial Interventions Such As CM Remain the Mo...mentioning

confidence: 99%

Section: The Current State Of Evidence For Clinical Use Of Pps For Th...mentioning

confidence: 99%

Section: A (Not So) New Care‐model Proposalmentioning

confidence: 99%

See 1 more Smart Citation

Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…21 Behavioral or psychosocial interventions should be combined with the medication to maximize medication adherence and minimize treatment dropout. 22 Where possible, patients should receive case-management services and harm-reduction interventions, further improving attractiveness of the program.…”

Section: Design Of Future Studiesmentioning

confidence: 99%

Continuing Increase in Stimulant Dependence – Time to Implement Medical Treatment

et al. 2022

Self Cite

View full text Add to dashboard Cite

The use of stimulant substances for non-medical purposes critically contributes to global problems related to substance use. Over 27 million people worldwide have used amphetamines, methamphetamines, and prescription psychostimulants, and around 19 million have used cocaine in 2018. 1 An increase in the burden of (psycho)stimulant use disorder (PSUD), both amphetamine-type (AUD) and cocaine-type (CUD), reflect those trends. From 2008 to 2017, the disability-adjusted life years (DALYs) attributable to CUD increased by 17% and AUD by 5%. The economic burden of PSUD varies across income status with CUD and AUD accounting in 2019 for 0.01 and 0.02% of the DALYs in low income and lower-middle income countries, as compared to 0.16% and 0.09 respectively in high income countries. 2 However, regional differences are also relevant: CUD is particularly burdensome in Tropical Latin America, where its prevalence is only outnumbered by North America; meanwhile, the regions with highest prevalence of AUD are East and South-East Asia. 3 Moreover, around 11.3 million people worldwide use drugs intravenously including opioids, amphetamines, methamphetamines, and cocaine. The concurrent use of an injected stimulant and an opioid increases the risk of medical problems, overdoses, and deaths in comparison to the injection of only one substance. 1,3 In the US, up to a third of opioid overdose deaths involved the concurrent use of a stimulant.

show abstract

“…In the meantime, psychotherapies for methamphetamine use can be effective . Contingency management, in which abstinence from methamphetamine use is encouraged with progressive reinforcement, has also been encouraged, particularly in combination with other psychotherapies such as community reinforcement approach, in both individual studies and systematic reviews . Despite this positive track record, contingency management plus other psychotherapies are not widely used and deserve further consideration .…”

mentioning

confidence: 99%

Reducing negative consequences from use of methamphetamine

2020

View full text Add to dashboard Cite

Contingency Management with pharmacologic treatment for Stimulant Use Disorders: A review

Cited by 19 publications

References 58 publications

Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach

Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach

Continuing Increase in Stimulant Dependence – Time to Implement Medical Treatment

Reducing negative consequences from use of methamphetamine

Contact Info

Product

Resources

About